Sechenov School
Home › Pharmacology › Azathioprine

Azathioprine

Azathioprinum

For medical students2 min readUpdated 2026-10-10

Azathioprine is a classic immunosuppressive agent that suppresses immune system activity by halting cell division. Historically, it was the first pharmacological agent that allowed the widespread clinical implementation of donor organ transplantation by solving the problem of rapid graft rejection.

Pharmacological groupImmunosuppressive agent
MetabolismProdrug; activated in the liver to 6-mercaptopurine
Target of actionNucleic acid synthesis (DNA and RNA)
Dangerous interactionAllopurinol dramatically increases toxicity risk

Classification and Historical Role

Azathioprine (Azathioprinum) is a classical immunosuppressive agent. The primary goal of drugs in this pharmacological group is the artificial reduction of the patient's immune activity.

In the history of medicine and pharmacology, this drug holds a pioneering status. Historically, it was the first medication widely introduced into routine organ transplantation practice. Before its advent, foreign tissue transplantation was invariably accompanied by an aggressive immune reaction, but the introduction of this immunosuppressant allowed physicians to successfully control this process.

Pharmacokinetics: The Prodrug Pathway

A crucial feature of the drug is that it is a prodrug. In its original form, the molecule does not possess immunosuppressive properties. To become active, the substance must undergo a complex biotransformation pathway within the body.

This process occurs in several stages:

  1. After administration, the drug is metabolized in the liver, where it is converted into its first active derivative — 6-mercaptopurine.
  2. Subsequently, 6-mercaptopurine undergoes further biochemical reactions and is transformed into the final working metabolite — 6-thio-GTP (guanosine triphosphate).

It is this final compound that is responsible for all subsequent pharmacological effects within cells.

Mechanism of Action: Molecular Blockade

The core mechanism of the drug unfolds at the level of the cell's genetic material. The resulting metabolite (6-thio-GTP) structurally resembles the natural nitrogenous bases from which nucleic acids are built.

During cell preparation for division, this metabolite is incorporated into the synthesized DNA and RNA chains instead of normal bases. This incorporation leads to fatal structural defects within the molecules, completely blocking further nucleic acid synthesis.

The logical outcome of this molecular blockade is a marked reduction in the proliferation (replication) of immune cells. The drug effectively suppresses the division of both T lymphocytes and B lymphocytes, depriving the immune system of its ability to mount a full-scale response against the body's own tissues or a graft.

Indications for Clinical Use

The drug's ability to reliably inhibit T- and B-lymphocyte proliferation determines its spectrum of clinical applications. It is prescribed in cases where the immune system acts against the patient's own body or threatens the survival of donor tissues.

Key indications include:

Dangerous Drug Interactions

When prescribing therapy, physicians must carefully monitor concurrent medications due to critical drug interactions.

A particular hazard arises from concurrent use with allopurinol. This drug specifically inhibits the metabolism of active mercaptopurine derivatives.

Clinical consequence: Because active metabolites are no longer properly degraded, there is a sharp intensification and significant prolongation of azathioprine's pharmacological action. This creates a high risk of severe toxicity in the body, necessitating mandatory dosage adjustments.

Mnemonic

Azathioprine is a "typo" in the genetic text. The metabolite (6-thio-GTP) incorporates into the DNA/RNA chain instead of a normal letter, making further reading (nucleic acid synthesis) impossible, so the cell cannot divide.

Frequently asked questions

In which autoimmune diseases is azathioprine indicated?

Azathioprine is used in the following autoimmune diseases and conditions of autoimmune nature:

  • Rheumatoid arthritis;
  • Systemic lupus erythematosus;
  • Ulcerative colitis;
  • Crohn's disease — including maintenance therapy after surgery or after achieving medical remission;
  • Autoimmune hepatitis in children — as part of combination therapy with glucocorticoids;
  • Recurrent pericarditis of autoimmune origin — when colchicine is ineffective or steroid dependency develops.
Which enzyme does allopurinol block, disrupting azathioprine metabolism?

Allopurinol blocks the enzyme xanthine oxidase. Azathioprine is a prodrug metabolized in the liver to active 6-mercaptopurine, which is normally inactivated by xanthine oxidase. Co-administration inhibits this enzyme, slowing the metabolism of active derivatives. Consequently, azathioprine action is enhanced and prolonged, drastically increasing toxicity, primarily bone marrow suppression.

What specific adverse effects does azathioprine cause?

Azathioprine therapy carries the risk of several severe adverse effects. Specific complications include:

  • Bone marrow suppression — manifesting as leukopenia and other cytopenias;
  • Hepatotoxicity — risk of toxic hepatitis;
  • Infectious complications — increased susceptibility to bacterial, viral, and fungal infections;
  • Secondary oncogenesis — increased risk of lymphoma and leukemia;
  • Teratogenic effect — disruption of embryonic development.
What are the absolute contraindications to azathioprine?

Contraindications to the use of azathioprine include pregnancy and lactation.

Does the drug affect the immune system immediately after administration?

No, because it is a prodrug. First, it must undergo hepatic metabolism into 6-mercaptopurine, and then convert into the active 6-thio-GTP. Only after this does the suppression of immune responses begin.

How exactly does the drug stop lymphocyte division?

Its active metabolite incorporates into DNA and RNA chains instead of normal bases. This causes structural defects that block further nucleic acid synthesis, causing the cell to lose its proliferative capacity.

Which immune system cells are the main target?

The drug causes non-selective suppression of proliferation, equally effectively inhibiting the replication of both T lymphocytes and B lymphocytes.

Why is it dangerous to prescribe allopurinol to patients taking this immunosuppressant?

Allopurinol inhibits the metabolism of active mercaptopurine derivatives. This leads to uncontrolled enhancement and prolongation of the immunosuppressant's effect, exponentially increasing the risk of severe toxicity.

Go deeper

More topics in Pharmacology

Chronic Obstructive Pulmonary DiseaseAntidiarrheal DrugsAntihypertensive DrugsVasopeptidase InhibitorsOprelvekinSelective Serotonin Reuptake InhibitorsRoflumilastDrug MetabolismCentral Non-Opioid AnalgesicsAnticholinergics in OphthalmologyCardioselective Beta-BlockersProbioticsPharmacology →